Pembrolizumab immunotherapy for relapsed CNS Lymphoma

Jerome J. GraberDepartment of Neurology, Benjamin and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, USA; ;Alvord Brain Tumor Center, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA; Correspondence[email protected]

http://orcid.org/0000-0001-5357-2932

Benjamin PlatoDepartment of Neurology, Benjamin and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, USA; ;Alvord Brain Tumor Center, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA;

Raya MawadDepartment of Medical Oncology, Swedish Cancer Institute, Seattle, WA, USA;

Daniel J. MooreDepartment of Community Oncology, Evergreen Health, Seattle Cancer Care Alliance, Seattle, WA, USA

Click to increase image sizeClick to decrease image size

Disclosure statement

Jerome Graber reports serving in the past on advisory boards for Novocure, Inc, Stemedica, Inc. and Abbvie as well as currently serving on the editorial boards of Neuro-oncology: Practice and Journal of Neuroimaging. No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Pembrolizumab immunotherapy for relapsed CNS Lymphoma

Information for

Open access

Opportunities

Help and information

Pembrolizumab immunotherapy for relapsed CNS Lymphoma

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature